摘要
非小细胞肺癌(NSCLC)患者常见脑转移,发病率为25%~40%,预后极差且常伴有严重神经功能障碍,未经治疗平均中位生存期仅为1~2个月。靶向治疗和免疫治疗为NSCLC脑转移患者治疗开辟了新的途径,改善脑转移后神经功能障碍,延长中位生存期。本文就NSCLC脑转移靶向治疗及免疫治疗进展进行综述。
Brain metastases are common in patients with non-small cell lung cancer(NSCLC),with an incidence of 25%~40%. Patients with brain metastases possesses poor prognosis associated with severe neurological dysfunction,which exhibit only1~2 months of mean median survival without treatment. Targeted therapy and immunotherapy have opened up a new way for the treatment of patients with NSCLC brain metastasis,which can improve neurological dysfunction after brain metastasis and prolong median survival time. This article reviews progress of targeted therapy and immunotherapy for NSCLC with brain metastasis.
作者
张语涵
李姗姗(指导)
刘浩(指导)
ZHANG Yuhan;LI Shanshan;LIU Hao(School of Pharmacy,Bengbu Medical College,Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals,Bengbu 233030,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2022年第14期1788-1792,F0003,F0004,共7页
Chinese Journal of Immunology
基金
国家“重大新药创制”科技重大专项(2019ZX09303001)
安徽省科技重大专项(201903a07020029)
安徽省学术技术带头人及后备人选科研活动经费(2019H215)
安徽省创新创业领军人才特殊支持计划项目资助。
关键词
非小细胞肺癌
脑转移
分子靶向治疗
免疫治疗
Non-small cell lung cancer
Brain metastasis
Molecular targeted therapy
Immunotherapy